Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells

Keyphrases

• Epstein-Barr Virus 100%
• Valproic Acid 100%
• Lymphoma Cells 100%
• Antitumor Activity 100%
• Natural Killer 100%
• Bortezomib 30%
• Natural Killer Cells 30%
• Killing Effect 30%
• Epstein-Barr Virus-positive 23%
• Reduced Cell 15%
• Histone Deacetylase Inhibitor (HDACi) 15%
• Cell Viability 15%
• Jurkat 15%
• No Significant Difference 7%
• T Cells 7%
• Peripheral Blood Mononuclear Cells 7%
• Induced Apoptosis 7%
• Tumor Cells 7%
• B Cells 7%
• Cell Cycle Arrest 7%
• Anticancer Effect 7%
• Antitumor Effect 7%
• Lytic Infection 7%
• Synergistic Effect 7%
• Virus-infected Cell 7%
• Acid Activation 7%
• Histone Deacetylase 1 (HDAC1) 7%
• Protease Inhibitors 7%
• Lymphoid Malignancies 7%
• Lymphoproliferative Disorders 7%
• Uninfected Cells 7%
• Acetylated Histone 7%

Medicine and Dentistry

• Epstein Barr Virus 100%
• Natural Killer Cell Lymphoma 100%
• Antineoplastic Activity 100%
• Sodium Valproate 100%
• Cell Line 30%
• Bortezomib 30%
• Natural Killer Cell 30%
• Histone Deacetylase Inhibitor 15%
• Cell Viability 15%
• Lymphoma 7%
• Tumor Cell 7%
• Programmed Cell Death 7%
• Infection 7%
• Cell Cycle Arrest 7%
• T Cell 7%
• Peripheral Blood Mononuclear Cell 7%
• Histone 7%
• B Cell 7%
• Lymphoproliferative Disease 7%
• Cell Cycle Checkpoint 7%
• Histone Deacetylase 7%
• Proteasome Inhibitor 7%

Immunology and Microbiology

• Antineoplastic Activity 100%
• Lymphoma Cell 100%
• Epstein Barr Virus 100%
• Cell Line 50%
• Natural Killer Cell 50%
• Cell Viability 25%
• B Cell 12%
• Cell Cycle Arrest 12%
• Tumor Cell 12%
• T Cell 12%
• Proteasome 12%
• Cell Cycle Checkpoint 12%
• Peripheral Blood Mononuclear Cell 12%